CombiMatrix rises on deal with pathology service provider

Pathology service provider ProPath selects CombiMatrix (CBMX) to "provide its chromosomal microarray analysis testing for miscarriage analysis."

"For an important group of patients, CMA testing can play a significant role in a comprehensive miscarriage analysis," a ProPath director notes.

CBMX says the agreement is "yet another validation of the quality of [its] diagnostic services." (PR)

CBMX +14% premarket.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs